Evaluating Cerebral micro-bleeding cHanges to Optimise anticoagulation thErapy in Stroke patients with Atrial Fibrillation
Lead PI: Dr. Zien Zhou
No. of Patients Currently Recruited: No. of Patients Required: 200
ECHOES-AF Pilot is an investigator-led Phase II randomised controlled trial to provide evidence on the safety of lower-dose non-vitamin K antagonist oral anticoagulants (NOACs) versus standard-dose NOACs in stroke patients with atrial fibrillation (AF) and cerebral microbleeds (CMBs). The primary outcome will be all-cause death. This study will be conducted in multiple hospitals and clinic-based centres across Australia. The planned number of participants for this pilot trial is 200, and the follow-up period is 12 months. The study is funded by NSW Health and The George Institute for Global Health, with Dr. Zien Zhou as Chief Investigator. Findings from this trial will help ascertain whether a very large clinical trial to identify optimal anticoagulation strategies for stroke patients with AF and CMBs will be possible.
